R. Donald Harvey

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

David Siegel, Thomas G Martin, A. Nooka et al. · Haematologica · 2013 · 344 citations · Full text

Medicine, Hematology, Pharmacology +11

Withaferin A inhibits breast cancer invasion and metastasis at sub‐cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation

Jose Thaiparambil, Laura Bender, Thota Ganesh et al. · International Journal of Cancer · 2011 · 285 citations · Full text

Medicine, Cell Biology, Pharmacology +14

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Wei-Gang Tong, Rong Chen, William Plunkett et al. · Journal of Clinical Oncology · 2010 · 218 citations

Medicine, Oncology, Pharmacology +17

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Paul G. Richardson, Rachid Baz, Michael Wang et al. · Blood · 2014 · 202 citations · Full text

Medicine, Hematology, Pharmacology +15

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey

David Waterhouse, R. Donald Harvey, Patricia A. Hurley et al. · JCO Oncology Practice · 2020 · 201 citations

Medicine, Oncology, Cancer Control +15